Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BRAF V600X |
Therapy | Vemurafenib |
Indication/Tumor Type | colorectal cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600X | colorectal cancer | no benefit | Vemurafenib | Phase II | Actionable | In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) in colorectal cancer patients with BRAF V600 mutations did not result in clinical benefit, with no patients achieving response, and 50% (5/10) demonstrating progressive disease (PMID: 26287849). | 26287849 |
PubMed Id | Reference Title | Details |
---|---|---|
(26287849) | Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. | Full reference... |